research Prospective Clinical Evaluation of Cross-Linked Hyaluronic Acid Dermal Filler (30 mg) for Facial Rejuvenation
The dermal filler is safe and effective for improving facial appearance.
Search
forProducts matching "clinical severity"
Tracking 4 products like 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL and 183 PROPECIA 1MG/*28 TABL from by companies like OnlinePharmacy-BG, Inhouse Pharmacy, oasisstad.net and oxfordon line pharmacy. View all 4 products »
Sort by
Research
30-60 / 1000+ resultsresearch Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
Ritlecitinib effectively regrows hair in treatment-resistant alopecia areata with mild side effects.
research Pilot Clinical Evaluation of a Hyaluronic Acid– and Hydrogen Peroxide–Based Gel in the Management of Folliculitis: An Open-Label, Post-Marketing Study
The gel effectively reduced folliculitis symptoms and was safe to use.
research CLINICAL INSIGHTS FROM “A STUDY TO EVALUATE THE EFFICACY OF PIX LIQUIDA FOR INDIVIDUALS SUFFERING FROM ALOPECIA AREATA”: A CASE REPORT
Pix Liquida helped a man recover from patchy hair loss.
research Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment
There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
research Short‐ and Long‐Term Clinical Skin Effects of Testosterone Treatment in Trans Men
Testosterone treatment in trans men increases body and facial hair and may lead to hair loss over time, but severe skin issues are rare.
research A clinical study on alopecia areata
Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
research Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
research Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*
Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Comparative Evaluation of Efficacy Between Topical Calcipotriol Used Along With Topical Clobetasol And Topical Clobetasol Monotherapy In Treatment Of Alopecia Areata: A Randomised Clinical Trial
Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
research Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
Alopecia areata in Brazil causes significant psychosocial impacts, with limited access to advanced treatments, especially in public healthcare.
research COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL
Tofacitinib works better than methotrexate for severe alopecia in the short term.
research Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial
Topical flutamide works as well as hydroquinone for melasma but needs more safety checks.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial
Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.
research Ageing-Related Features of Hair and Scalp in Chinese Women by Clinical Evaluation Study
Chinese women's hair gets thinner and grayer with age, and scalp conditions change, especially after 40.
research Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel
Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
research Intradermal platelet-rich plasma for the treatment of melasma: A clinical and dermoscopic evaluation in dark skin
Intradermal PRP significantly improved melasma in dark skin, with lasting results and no relapse after 3 months.
research The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial
Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Umbilical cord as a source of mesenchymal stem cells improves melasma in parturients: a clinical randomized trial
Umbilical cord masks can help reduce melasma in postpartum women.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.